Finoriq research workspace
ALUMIS INC. (ALMS) Company Overview
ALUMIS INC. offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque. Review ALMS filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- Company
- ALUMIS INC. (ALMS)
- Ticker
- ALMS
- Market Cap
- $3.6B
- Latest Price
- $28.3
- Industry
- Biotech & Pharma
ALUMIS INC. (ALMS) Current Valuation Metrics
Static valuation preview for ALUMIS INC. (ALMS). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 159x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -6.3% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -9.6% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 12.7x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.